{"id":8491,"date":"2013-07-12T03:41:07","date_gmt":"2013-07-12T07:41:07","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=8491"},"modified":"2013-07-12T03:41:07","modified_gmt":"2013-07-12T07:41:07","slug":"progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491","title":{"rendered":"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#8217;s chief product candidate is PSMA ADC"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 07\/12\/2013 (wallstreetpr) &#8211;\u00a0Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)\u2019s<b> <\/b>stock closed at $5.70. The opening of the stock was at $5.15 and it made an intraday high at $5.72. In trading session on Thursday, no shares were traded as against the average volume of 527,781.00 shares in the last 90 trading sessions.<\/p>\n<p style=\"text-align: justify;\">Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a biopharmaceutical Company that actively conducts research and development for products candidates of biotechnology in virology, oncology, gastroenterology and supportive care. The Company also conducts research for identifying multiplex phosphoinositide 3-kinase inhibitors to block signaling pathways in the aggressive cancers\u2019 growth. The Company\u2019s foremost commercial product in gastroenterology is RELISTOR subcutaneous injection. The chief product candidate of the Company is PSMA ADC which is a completely human monoclonal antibody-drug conjugate aimed against prostate specific membrane antigen.<\/p>\n<p style=\"text-align: justify;\">As per the reports by TheFlyOnTheWall.com, Progenics Pharmaceuticals (NASDAQ: PGNX)\u00a0got an upgraded rating of \u201cbuy\u201d from the previous \u201chold\u201d rating by Brean Capital\u2019s equities researchers. The report was issued on Monday. Presently, the stock of the firm has been given a price target of $9.00.<\/p>\n<p style=\"text-align: justify;\">The quarterly earnings results of Progenics Pharmaceuticals (NASDAQ: PGNX) was last published on Friday, May 10th. In the report, the company showed Earnings per Share (EPS) of $0.22 for the quarter. This figure missed the previously estimated amount of by $0.33. The consensus amount was set at $0.19. The revenue of the Company for the quarter stood at $2.23 million. The consensus estimate of the quarter\u2019s revenue was $1.71 million. \u00a0In the previous year, for the same quarter, $0.39 Earnings per Share were posted by the Company. It is predicted by the analysts that on an average, Progenics Pharmaceuticals (NASDAQ: PGNX) will post earnings per share of $-0.75 for the current fiscal year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 07\/12\/2013 (wallstreetpr) &#8211;\u00a0Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)\u2019s stock closed at $5.70. The opening of the stock was at $5.15 and it made an intraday [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":8492,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1937,2602],"stock_ticker":[],"class_list":["post-8491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqpgnx","tag-progenics-pharmaceuticals-inc-nasdaqpgnx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#039;s chief product candidate is PSMA ADC - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#039;s chief product candidate is PSMA ADC - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 07\/12\/2013 (wallstreetpr) &#8211;\u00a0Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)\u2019s stock closed at $5.70. The opening of the stock was at $5.15 and it made an intraday [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-07-12T07:41:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#8217;s chief product candidate is PSMA ADC\",\"datePublished\":\"2013-07-12T07:41:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\"},\"wordCount\":298,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg\",\"keywords\":[\"NASDAQ:PGNX\",\"Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\",\"name\":\"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s chief product candidate is PSMA ADC - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg\",\"datePublished\":\"2013-07-12T07:41:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#8217;s chief product candidate is PSMA ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s chief product candidate is PSMA ADC - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491","og_locale":"en_US","og_type":"article","og_title":"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s chief product candidate is PSMA ADC - Wall Street PR","og_description":"Boston, MA 07\/12\/2013 (wallstreetpr) &#8211;\u00a0Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)\u2019s stock closed at $5.70. The opening of the stock was at $5.15 and it made an intraday [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-07-12T07:41:07+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#8217;s chief product candidate is PSMA ADC","datePublished":"2013-07-12T07:41:07+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491"},"wordCount":298,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg","keywords":["NASDAQ:PGNX","Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491","url":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491","name":"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s chief product candidate is PSMA ADC - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg","datePublished":"2013-07-12T07:41:07+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/download5.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/progenics-pharmaceuticals-inc-nasdaqpgnxs-chief-product-candidate-is-psma-adc-8491#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)&#8217;s chief product candidate is PSMA ADC"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/8491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=8491"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/8491\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/8492"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=8491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=8491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=8491"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=8491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}